Participants in the study will be randomly assigned to receive either Letrozole or standard chemotherapy. The chemotherapy treatments being used in this study include Carboplatin and Paclitaxel. Carboplatin is a drug that interferes with the DNA of cancer cells, preventing them from dividing and growing. Paclitaxel, also known by code names such as Oncogel and ABI-007, works by stopping cancer cells from dividing. The study will monitor participants over a period to see which treatment is more effective in delaying the progression of the cancer.

The main goal of the study is to determine if Letrozole can provide a longer period without the cancer worsening compared to the standard chemotherapy. Participants will receive regular check-ups and assessments to track their health and the status of their cancer. The study will help researchers understand which treatment option might be better for patients with this specific type of ovarian cancer.

The purpose of the study is to determine if taking niraparib after three cycles of chemotherapy is as effective as taking it after six cycles. The study will involve patients receiving either three or six cycles of chemotherapy, followed by maintenance treatment with niraparib. Some patients may receive a placebo instead of niraparib to compare the outcomes. The study aims to see if the shorter treatment duration can provide similar benefits in preventing cancer from returning.

Participants in the study will be monitored over time to assess their health and any side effects from the treatments. The study will also look at how long patients live without the cancer coming back and their overall survival rates. The trial will help determine the best approach to using niraparib in treating these types of cancer, potentially offering a more efficient treatment option for patients in the future.

The purpose of this research is to determine if adding both niraparib and dostarlimab to standard platinum-based therapy improves how long patients can live without their cancer getting worse, compared to using just niraparib with platinum-based therapy. Dostarlimab is a type of medication known as an anti-PD-1 monoclonal antibody that helps the immune system fight cancer cells, while niraparib works by blocking certain proteins that help cancer cells repair themselves.

During the study, which may last up to 72 months, participants will receive either the combination of both study medications with standard therapy, or standard therapy with just one study medication, or standard therapy with placebo. The niraparib or matching placebo will be taken daily as capsules, while dostarlimab or its matching placebo will be given through an infusion into a vein. Throughout the study, participants will have regular medical check-ups to monitor their health and how well the treatment is working.

The trial involves several medications that are used during the treatment process. These include Paclitaxel Eugia, a solution for infusion that helps stop cancer cells from growing, and Sodium Thiosulfate, which is used to reduce side effects. Another medication used is Avastin, which works by preventing the growth of blood vessels that supply the tumor. Additionally, Cisplatin and Carboplatin are used, both of which are types of chemotherapy that help kill cancer cells. These medications are administered through an intravenous infusion, meaning they are given directly into a vein.

Participants in the study will undergo the primary cytoreductive surgery, and some will receive the additional HIPEC treatment. The study will monitor the patients over time to see how the treatments affect their survival and if the cancer returns. The goal is to determine if the combination of surgery and HIPEC provides a better outcome for patients with stage III epithelial ovarian cancer compared to surgery alone. The study will also look at the time it takes for patients to need further cancer treatment and any side effects experienced during the treatment period.

In addition to carboplatin and paclitaxel, the study will also involve the use of bevacizumab, a medication that helps prevent the growth of blood vessels that supply the tumor, and filgrastim, which is used to boost white blood cell counts and help the body fight infections during chemotherapy. Some patients in the study will receive a placebo instead of bevacizumab to compare the effects. The trial aims to determine if the new treatment plan can improve outcomes for patients, such as increasing the chances of successful surgery and extending survival times.

Participants in the study will receive treatment over a period of up to 64 weeks. The study will monitor various outcomes, including the overall response to treatment, progression-free survival (the time during which the cancer does not get worse), and overall survival. The trial will also assess the quality of life of participants and gather information on any side effects experienced. The findings from this study could help improve treatment strategies for patients with ovarian cancer who have a poor prognosis.

Participants in the study will receive tinzaparin through subcutaneous injections, which means the medication is administered under the skin. The study will monitor changes in CA-125 levels before and during chemotherapy cycles, as well as before surgery. Additionally, other health indicators such as hemoglobin, platelets, and certain proteins will be measured throughout the treatment period. The study will also assess how well patients adhere to the tinzaparin injections and any side effects they may experience.

The trial is designed to provide valuable insights into the potential benefits of tinzaparin for ovarian cancer patients, particularly in managing the disease and improving treatment outcomes. By understanding the effects of tinzaparin on these biological markers, researchers hope to enhance the overall care and treatment strategies for individuals battling this challenging condition.